Aurobindo Pharma Ltd
NSE:AUROPHARMA
Relative Value
The Relative Value of one
AUROPHARMA
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 1 231 INR,
Aurobindo Pharma Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
AUROPHARMA Competitors Multiples
Aurobindo Pharma Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Aurobindo Pharma Ltd
NSE:AUROPHARMA
|
715B INR | 2.1 | 20.3 | 9.4 | 12.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
966.3B USD | 14.9 | 47 | 31.7 | 33.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.6B USD | 6.2 | 22 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
291.9B CHF | 4.8 | 31.2 | 13.1 | 15.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.6B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.5 | 31.5 | 17.4 | 24.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.1B USD | 4.6 | 16.4 | 10.3 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123B USD | 2.6 | 17.5 | 7.3 | 9 |